menu
    • menu
    [{"orgOrder":0,"company":"LaviPharm","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GREECE","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"LaviPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LaviPharm \/ LaviPharm","highestDevelopmentStatusID":"15","companyTruncated":"LaviPharm \/ LaviPharm"},{"orgOrder":0,"company":"LaviPharm","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"LaviPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LaviPharm \/ LaviPharm","highestDevelopmentStatusID":"15","companyTruncated":"LaviPharm \/ LaviPharm"}]

    Find Clinical Drug Pipeline Developments & Deals by LaviPharm

    Menu

    LaviPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LaviPharm

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LaviPharm

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Caffeine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Famar

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FAMAR and Lavipharm Collaborate on Pharmaceutical Product Production

                            Details : Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).

                            Product Name : Lonarid N

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Paracetamol,Caffeine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Famar

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LaviPharm

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LaviPharm

                            Greece arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Asset Purchase Agreement for Lavipharm

                            Details : Company acquires two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, used for fever and pain, for Greece and Cyprus markets with the intention to commercialize them internationally.

                            Product Name : Lonarid N

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 01, 2023

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth